Keytruda, a medication produced by Merck & Co., received its initial approval from the U.S. Food and Drug Administration (FDA) for cancer treatment in 2014. This approval was specifically for the treatment of advanced melanoma in patients who had previously received other forms of treatment [1].

Since its initial approval, Keytruda has received additional approvals from the FDA for the treatment of various types of cancer, including certain types of lung, head and neck, and bladder cancers [1].

It is important to note that, as a biologic medication, Keytruda is covered by patents that grant Merck exclusive rights to manufacture and sell the drug in the United States until those patents expire [2]. According to DrugPatentWatch.com, Keytruda's first patent is set to expire in 2028 [3]. After this date, other companies may be able to produce and sell generic versions of the drug, potentially increasing accessibility and reducing costs for patients.

In summary, Keytruda received initial FDA approval for cancer treatment in 2014 and is currently covered by patents that will expire in 2028.

Sources:

* [1] U.S. Food and Drug Administration. (2022). Keytruda (pembrolizumab) prescribing information. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125514s116lbl.pdf>
* [2] Merck & Co., Inc. (2022). Intellectual property. Retrieved from <https://www.merck.com/about/company-financials/intellectual-property.html>
* [3] DrugPatentWatch.com. (2022). Keytruda (pembrolizumab) patents. Retrieved from <https://www.drugpatentwatch.com/drugs/keytruda>